Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Nov;74(10):1598–1604. doi: 10.1038/bjc.1996.595

Fibronectin promotes the proliferation of cytotoxic T lymphocytes generated from cancer patients.

S Mizobata 1, H Tanimura 1, H Yamaue 1, M Tani 1, T Tsunoda 1, M Iwahashi 1, K Noguchi 1, N Nishimoto 1, T Hotta 1, K Arii 1
PMCID: PMC2074855  PMID: 8932341

Abstract

We studied whether fibronectin (FN) enhances the activity of autologous tumour-reactive cytotoxic T lymphocytes (CTLs) generated from cancer patients. The proliferation of CTLs stimulated by immobilised anti-CD3 monoclonal antibody and interleukin 2 (IL-2) was enhanced three or four times by immobilised FN. whereas soluble FN did not alter the DNA synthesis of CTLs. Moreover, the cytotoxic activity of CTLs was augmented by FN stimulation against autologous tumour cells [4 h 51Cr release assay: FN(+) 16.7 +/- 4.7% vs FN (-) 11.8 +/- 3.1%; 16 h 51Cr release assay: FN(+) 24.8 +/- 4.7% vs FN (-) 16.5 +/- 5.7%, P<0.05]. The major cell surface phenotype of CTLs with FN was CD3+, CD4+ and CD25+ in 6 weeks' culture. Cytotoxicity against autologous tumour cells was inhibited by anti-HLA class I monoclonal antibody (MAb). The autologous tumour-killing activity of CTLs was suppressed by the elimination of CD4+ cells. Moreover, the cytokine production of CTLs was augmented by FN stimulation. Especially, the production of IL-2, interferon gamma (IFN-gamma), and granulocyte macrophage colony-stimulating factor (GM-CSF) was significantly augmented by FN stimulation (P<0.05). Thus, CTLs generated by FN might have both killer and helper functions, since they could lyse autologous tumour cells and secrete various cytokines, including IL-2.

Full text

PDF
1598

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aruga A., Yamauchi K., Takasaki K., Furukawa T., Hanyu F. Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. Int J Cancer. 1991 Aug 19;49(1):19–24. doi: 10.1002/ijc.2910490105. [DOI] [PubMed] [Google Scholar]
  2. Cardarelli P. M., Yamagata S., Scholz W., Moscinski M. A., Morgan E. L. Fibronectin augments anti-CD3-mediated IL-2 receptor (CD25) expression on human peripheral blood lymphocytes. Cell Immunol. 1991 Jun;135(1):105–117. doi: 10.1016/0008-8749(91)90258-d. [DOI] [PubMed] [Google Scholar]
  3. Davis L. S., Oppenheimer-Marks N., Bednarczyk J. L., McIntyre B. W., Lipsky P. E. Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. J Immunol. 1990 Aug 1;145(3):785–793. [PubMed] [Google Scholar]
  4. Firestein G. S., Roeder W. D., Laxer J. A., Townsend K. S., Weaver C. T., Hom J. T., Linton J., Torbett B. E., Glasebrook A. L. A new murine CD4+ T cell subset with an unrestricted cytokine profile. J Immunol. 1989 Jul 15;143(2):518–525. [PubMed] [Google Scholar]
  5. Ioannides C. G., Rashed S., Fisk B., Fan D., Itoh K., Freedman R. S. Lymphocytes infiltrating ovarian malignant ascites: modulation of IL-2-induced proliferation by IL-4 and of selective increase in CD8+ T cells by TNF-alpha. Lymphokine Cytokine Res. 1991 Aug;10(4):307–315. [PubMed] [Google Scholar]
  6. Itoh K., Salmeron M. A., Morita T., Seito D., Mansfield P. F., Ross M. I., Balch C. M., Augustus L. B. Distribution of autologous tumor-specific cytotoxic T lymphocytes in human metastatic melanoma. Int J Cancer. 1992 Aug 19;52(1):52–59. doi: 10.1002/ijc.2910520112. [DOI] [PubMed] [Google Scholar]
  7. Iwahashi M., Tanimura H., Yamaue H., Tsunoda T., Tani M., Tamai M., Noguchi K., Hotta T. Defective autologous mixed lymphocyte reaction (AMLR) and killer activity generated in the AMLR in cancer patients. Int J Cancer. 1992 Apr 22;51(1):67–71. doi: 10.1002/ijc.2910510114. [DOI] [PubMed] [Google Scholar]
  8. Maeda N., Hamasato S., Miyazawa H., Takata M., Yamamoto H., Fujimoto S. Augmentation of human cytotoxic T lymphocytes against autologous tumor by a factor released from human monocytic leukemia cell line. Jpn J Cancer Res. 1989 Jun;80(6):537–545. doi: 10.1111/j.1349-7006.1989.tb01673.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Maggi E., Biswas P., Del Prete G., Parronchi P., Macchia D., Simonelli C., Emmi L., De Carli M., Tiri A., Ricci M. Accumulation of Th-2-like helper T cells in the conjunctiva of patients with vernal conjunctivitis. J Immunol. 1991 Feb 15;146(4):1169–1174. [PubMed] [Google Scholar]
  10. Malissen B., Rebai N., Liabeuf A., Mawas C. Human cytotoxic T cell structures associated with expression of cytolysis. I. Analysis at the clonal cell level of the cytolysis-inhibiting effect of 7 monoclonal antibodies. Eur J Immunol. 1982 Sep;12(9):739–747. doi: 10.1002/eji.1830120908. [DOI] [PubMed] [Google Scholar]
  11. Matsubayashi Y., Zenita K., Morioka A., Iwashiro M., Masuda T., Uchino H., Fujita T., Kuribayashi K. Characterization of a CD4(L3T4)-positive cytotoxic T cell clone that is restricted by class I major histocompatibility complex antigen on FBL-3 tumor cell. Immunobiology. 1989 Nov;180(1):33–46. doi: 10.1016/S0171-2985(89)80028-2. [DOI] [PubMed] [Google Scholar]
  12. Matsuyama T., Yamada A., Kay J., Yamada K. M., Akiyama S. K., Schlossman S. F., Morimoto C. Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex. J Exp Med. 1989 Oct 1;170(4):1133–1148. doi: 10.1084/jem.170.4.1133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mosmann T. R., Cherwinski H., Bond M. W., Giedlin M. A., Coffman R. L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986 Apr 1;136(7):2348–2357. [PubMed] [Google Scholar]
  14. Mosmann T. R., Schumacher J. H., Street N. F., Budd R., O'Garra A., Fong T. A., Bond M. W., Moore K. W., Sher A., Fiorentino D. F. Diversity of cytokine synthesis and function of mouse CD4+ T cells. Immunol Rev. 1991 Oct;123:209–229. doi: 10.1111/j.1600-065x.1991.tb00612.x. [DOI] [PubMed] [Google Scholar]
  15. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  16. Rosenberg S. A., Packard B. S., Aebersold P. M., Solomon D., Topalian S. L., Toy S. T., Simon P., Lotze M. T., Yang J. C., Seipp C. A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676–1680. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
  17. Sato T., Sato N., Takahashi S., Koshiba H., Kikuchi K. Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary cancer cells. Cancer Res. 1986 Sep;46(9):4384–4389. [PubMed] [Google Scholar]
  18. Shimizu Y., van Seventer G. A., Horgan K. J., Shaw S. Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J Immunol. 1990 Jul 1;145(1):59–67. [PubMed] [Google Scholar]
  19. Shimizu Y., van Seventer G. A., Horgan K. J., Shaw S. Roles of adhesion molecules in T-cell recognition: fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-5, VLA-6) in expression, binding, and costimulation. Immunol Rev. 1990 Apr;114:109–143. doi: 10.1111/j.1600-065x.1990.tb00563.x. [DOI] [PubMed] [Google Scholar]
  20. Tada T., Sano H., Sato S., Shima J., Fujiwara H., Hamaoka T. Immune dysfunction expressed selectively on L3T4+ T cells in the tumor-bearing state. J Leukoc Biol. 1990 Feb;47(2):149–157. doi: 10.1002/jlb.47.2.149. [DOI] [PubMed] [Google Scholar]
  21. Tani M., Tanimura H., Yamaue H., Mizobata S., Iwahashi M., Tsunoda T., Noguchi K., Tamai M., Hotta T., Terasawa H. Generation of CD4+ cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients. Int J Cancer. 1995 Mar 16;60(6):802–807. doi: 10.1002/ijc.2910600613. [DOI] [PubMed] [Google Scholar]
  22. Tsunoda T., Tanimura H., Yamaue H., Iwahashi M., Tani M., Tamai M., Arii K., Noguchi K. In vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patients. Int J Immunopharmacol. 1992 Jan;14(1):75–81. doi: 10.1016/0192-0561(92)90107-v. [DOI] [PubMed] [Google Scholar]
  23. Tsunoda T., Tanimura H., Yamaue H., Iwahashi M., Tani M., Tamai M., Arii K., Noguchi K. The promotive effect of interleukin 4 with interleukin 2 in the proliferation of tumor-infiltrating lymphocytes from patients with malignant tumor. Biotherapy. 1992;4(1):9–15. doi: 10.1007/BF02171704. [DOI] [PubMed] [Google Scholar]
  24. Wang P., Vánky F., Klein E. MHC class-I-restricted auto-tumor-specific CD4+CD8- T-cell clones established from autologous mixed lymphocyte-tumor-cell culture (MLTC). Int J Cancer. 1992 Jul 30;51(6):962–967. doi: 10.1002/ijc.2910510621. [DOI] [PubMed] [Google Scholar]
  25. Yamada A., Nikaido T., Nojima Y., Schlossman S. F., Morimoto C. Activation of human CD4 T lymphocytes. Interaction of fibronectin with VLA-5 receptor on CD4 cells induces the AP-1 transcription factor. J Immunol. 1991 Jan 1;146(1):53–56. [PubMed] [Google Scholar]
  26. Yamaue H., Katsumi M., Tabuse K., Tabuse Y., Kuribayashi K., Nishihara T., Saito K. Induction of activated natural killer cells from murine spleen cells primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432. Cancer Immunol Immunother. 1987;25(3):169–174. doi: 10.1007/BF00199143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Yamaue H., Tanimura H., Iwahashi M., Tani M., Tsunoda T., Tabuse K., Kuribayashi K., Saito K. Role of interleukin-2 and interferon-gamma in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432. Cancer Immunol Immunother. 1989;29(2):79–86. doi: 10.1007/BF00199281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Yamaue H., Tanimura H., Noguchi K., Hotta T., Tani M., Tsunoda T., Iwahashi M., Tamai M., Iwakura S. Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay. Br J Cancer. 1992 Nov;66(5):794–799. doi: 10.1038/bjc.1992.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Yamaue H., Tanimura H., Tsunoda T., Iwahashi M., Tani M., Tamai M., Inoue M. Functional and phenotypic analyses of interleukin 2-activated tumor-infiltrating lymphocytes. Biotherapy. 1990;2(3):247–259. doi: 10.1007/BF02173526. [DOI] [PubMed] [Google Scholar]
  30. Yamaue H., Tanimura H., Tsunoda T., Tani M., Iwahashi M., Noguchi K., Tamai M., Hotta T., Arii K. Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay. Eur J Cancer. 1991;27(10):1258–1263. doi: 10.1016/0277-5379(91)90093-s. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES